Artan Biotechnologies LLC has closed a $1 million seed round to support progression of the company’s proprietary mutation-specific codon suppression platform toward first-in-human development.

Artan Biotechnologies LLC has completed a $200,000 seed raise to fund preclinical advancement of the company’s proprietary engineered suppressor platform, which targets nonsense mutations.

Protuoso Biosciences has announced the close of an oversubscribed $9.5 million seed financing round, the proceeds of which will be used to advance its multifunctional protein engineering platform and broad pipeline across cardiometabolic, oncology and autoimmune diseases.